Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Biopharmaceutical company announces 32% revenue increase for second quarter 2004
September 8th, 2004
Novavax, Inc., (NASDAQ:NVAX) announced its financial results for the second quarter ended June 30, 2004. Total revenues for the second quarter rose 32% to $3.0 million compared to second quarter 2003 revenues of $2.3 million. Revenues for the second quarter included $2.7 million of product sales compared to $2.0 million in the prior year period, a $0.7 million or 36% increase. The increase in product sales was primarily due to the commercial launch of ESTRASORB, with initial orders to wholesalers generating sales of $1.5 million in June. While sales of Novavax's two new prenatal vitamin products continued to grow, sales of the company's vitamin...
Source: Vaccine Weekly (2004-09-08)
|
